Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase 2 Trial Assessing REGorafenib Combined With IRInotecan as Second-line Treatment in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

NCT03722108 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT03722108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03722108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase 2 Trial Assessing REGorafenib Combined With IRInotecan as Second-line Treatment in Patients With Metastatic Gastro-oesophageal Adenocarcinomas
Lead sponsor
UNICANCER
Phase
Phase 1/2
Overall status
Terminated
Start date
February 7, 2019
Completion date
May 19, 2022
Enrollment
89 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the gastroesophageal junction, adenocarcinoma of the stomach